Method for screening of therapeutic agent for hyperlipemia
| 外国特許コード | F170009204 |
|---|---|
| 整理番号 | A261-11WO |
| 掲載日 | 2017年9月12日 |
| 出願国 | 欧州特許庁（ＥＰＯ） |
| 出願番号 | 10833235 |
| 公報番号 | 2505660 |
| 公報番号 | 2505660 |
| 出願日 | 平成22年11月25日(2010.11.25) |
| 公報発行日 | 平成24年10月3日(2012.10.3) |
| 公報発行日 | 平成26年5月21日(2014.5.21) |
| 国際出願番号 | JP2010070959 |
| 国際公開番号 | WO2011065389 |
| 国際出願日 | 平成22年11月25日(2010.11.25) |
| 国際公開日 | 平成23年6月3日(2011.6.3) |
| 優先権データ |
|
| 発明の名称 （英語） | Method for screening of therapeutic agent for hyperlipemia |
| 発明の概要（英語） |
(EP2505660) Disclosed are a highly safe treatment method for hyperlipidemia and a therapeutic agent for hyperlipidemia. Specifically, the invention provides a novel method for screening an agent for treating hyperlipidemia, more specifically, a method for screening a substance that can inhibit the production or function of gangliosides, particularly GM3, or inhibit the activity or expression of GM3 synthase to reduce a blood lipid level. A pharmaceutical composition, which can specifically inhibit the production of gangliosides, particularly GM3, thereby effective for hyperlipidemia treatment, and others are also provided. |
| 特許請求の範囲（英語） |
[claim1] 1. A method for screening a substance having a blood lipid level lowering activity, which comprises: (i) contacting GM3 synthase with a substrate thereof in the presence or absence of a test substance, (ii) selecting a test substance that decreases the synthesized amount of GM3, (iii) administering the selected test substance to a non-human animal, and (iv) determining the blood lipid level in the non-human animal. [claim2] 2. A method for screening a substance having a blood lipid level lowering activity, which comprises: (i) contacting a test substance with a cell expressing GM3 synthase, (ii) selecting a test substance that decreases the expression level of GM3 synthase, (iii) administering the selected test substance to a non-human animal, and (iv) determining the blood lipid level in the non-human animal. [claim3] 3. The method according to claim 2, wherein the cell expressing GM3 synthase is selected from the group consisting of adipocytes, hepatocytes, vascular endothelial cells, vascular smooth muscle cells, skeletal muscle cells, epithelial cells, neurocytes, fibroblasts, monocytes and macrophages. [claim4] 4. The method according to claim 2, wherein the cell expressing GM3 synthase is a transformant produced by genetic engineering. [claim5] 5. The screening method according to any one of claims 1 to 4, which further comprises selecting a test substance that reduces a blood cholesterol level and/or a blood triglyceride level. [claim6] 6. The method according to any one of claims 1 to 5, wherein the non-human animal has a higher blood lipid level than normal level. [claim7] 7. The method according to any one of claims 1 to 6, wherein the non-human animal is a mouse. [claim8] 8. A pharmaceutical composition effective for treatment of hyperlipidemia, comprising a substance that specifically prevents a production of a ganglioside. [claim9] 9. The composition according to claim 8, wherein the ganglioside is GM3. [claim10] 10. A pharmaceutical composition effective for treatment of hyperlipidemia, comprising an antibody against GM3, a GM3 synthase inhibitor, or a substance that inhibits GM3 synthase expression. |
|
|
|
|
| 国際特許分類(IPC) |
|
| 欧州特許分類/主・副 |
|
| 指定国 |
(EP2505660) Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
| 参考情報 （研究プロジェクト等） | CREST Clarification of the Biological Functions of Sugar Chains and the Use of this Knowledge in Applied Technologies AREA |
日本語項目の表示
| 発明の名称 | 高脂血症治療剤のスクリーニング方法 |
|---|
※
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。
『 Method for screening of therapeutic agent for hyperlipemia 』に関するお問合せ
- 国立研究開発法人科学技術振興機構（ＪＳＴ） 知的財産マネジメント推進部
- URL: http://www.jst.go.jp/chizai/
-
E-mail:
- Address: 〒102-8666 東京都千代田区四番町5-3
- TEL: 03-5214-8293
- FAX: 03-5214-8476
※ 同じキーワードでJ-STORE内を検索することが出来ます。→ J-STORE内を検索
